Form 8-K - Current report:
SEC Accession No. 0001437749-24-034565
Filing Date
2024-11-12
Accepted
2024-11-12 16:24:10
Documents
16
Period of Report
2024-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K zvra20240819_8k.htm   iXBRL 8-K 33637
2 EXHIBIT 99.1 ex_716268.htm EX-99.1 184772
7 zvralogo.jpg GRAPHIC 6458
  Complete submission text file 0001437749-24-034565.txt   380244

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA zvra-20241112.xsd EX-101.SCH 3410
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE zvra-20241112_def.xml EX-101.DEF 11425
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE zvra-20241112_lab.xml EX-101.LAB 15311
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE zvra-20241112_pre.xml EX-101.PRE 11585
18 EXTRACTED XBRL INSTANCE DOCUMENT zvra20240819_8k_htm.xml XML 2849
Mailing Address 1180 CELEBRATION BOULEVARD, SUITE 103 CELEBRATION FL 34747
Business Address 1180 CELEBRATION BOULEVARD, SUITE 103 CELEBRATION FL 34747 (321) 939-3416
ZEVRA THERAPEUTICS, INC. (Filer) CIK: 0001434647 (see all company filings)

EIN.: 205894398 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36913 | Film No.: 241448662
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)